Improvement in advanced Alzheimer’s disease following psilocybin-containing mushroom administration

An interesting case-report caught my eye. Here is its abstract:

Background: 

Advanced Alzheimer’s disease (AD) is generally regarded as a stage of irreversible functional decline. Psilocybin is known to transiently alter large-scale brain network dynamics and to induce plasticity-related mechanisms in preclinical models, yet clinical data in advanced dementia remain lacking.

Case presentation: 

We report the case of an octogenarian Japanese-American woman with a 10-year history of Alzheimer’s disease, including 5 years of marked hypofunction and predominantly monosyllabic speech. Baseline features included chronic urinary incontinence, executive dysfunction, dysphagia, dependent mobility, flat affect, and severe reduction in spontaneous communication. The patient received 5 g of orally administered psilocybin-containing mushrooms (Enigma strain). The acute phase was marked by autonomic activation, clinically suspected hyperthermia, profuse sweating, and a prolonged deep sleep-like state. Approximately 19 h post-administration, spontaneous autobiographical speech emerged. Over subsequent days and weeks, functional improvements included restoration of urinary continence, improved ambulation, autonomous dressing, increased emotional responsiveness, sustained social interaction, contextual memory retrieval, preserved working memory for social context, and spontaneous conversational engagement.

Conclusion: 

This case documents transient multidomain functional improvement in advanced Alzheimer’s disease following psilocybin administration. The findings do not imply disease reversal but suggest that residual functional capacity may persist in late-stage neurodegeneration and may become transiently accessible under specific neuromodulatory conditions.

Of course, causality cannot be established with a case-report; the findings are therefore hypothesis-generating only. Plausible alternative explanations for the observed outcome include:

• Natural fluctuation in dementia severity or a transient “plateau” of improvement unrelated to psilocybin.
• Caregiver expectancy and observer bias, given that the same people who administered the intervention also documented the improvements.
• Confounding medical events (e.g., resolution of infection, metabolic correction, medication change) that were not systematically ruled out.
• Regression to the mean or random variation in functional status.

The lack of an objective endpoint (biomarker or imaging confirmation) of Alzheimer’s disease further weakens internal validity. Mixed pathology (vascular, Lewy body, frontotemporal) could produce different patterns of fluctuation and response. The absence of objective endpoints introduces subjective interpretation. “Autobiographical speech,” “improved continence,” and “better mobility” were not defined operationally or measured quantitatively.

The authors propose a plausible but speculative hypothesis: psilocybin’s disruption of the default mode network (DMN) and promotion of global functional integration may temporarily restore cross-network connectivity, allowing residual but inaccessible function to become expressed. This is consistent with psychedelic effects on network flexibility and DMN disruption, as well as with the idea that late-stage neurodegeneration may leave residual functional capacity that is normally inaccessible. However, the paper provides no neuroimaging, no electrophysiological data, and no direct evidence of network changes. The mechanism thus remains a hypothesis.

Still, the report does raise a question worthy of proper investigation: can psychedelic neuromodulation unmask residual function in late-stage neurodegeneration?